XGEVA Improves Metastasis-Free Survival In Castrate-Resistant Prostate Cancer
Cancer Care Cost To Jump by 27 Percent In a Decade, Reaching $158 Billion in 2020
Lilly Suspends Phase III Trial Of Tasisulam in Melanoma
Genomic Health Presents Meta-Analyses of Oncotype DX
In Phase II Study, NKTR-102 Shows Objective Response
Iniparib Plus Chemo Shows Benefit In Phase II Study
ColoPrint Improves Prognosis In Stage II and III Colon Cancer
Test May Identify Predictors For Recurrence Post-Surgery
Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out
- Shane Jacobson named CEO of the American Cancer Society, ACS CAN
- Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?